SCM
ORMP icon

Sage Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Sage Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.5K Hold
17,977
– – 0.03% 162
2026
Q1 		$61.1K Buy
17,977
+1,227
+7% +$4.16K 0.03% 163
2025
Q4 		$47.7K Hold
16,750
– – 0.02% 161
2025
Q3 		$44.2K Hold
16,750
– – 0.02% 157
2025
Q2 		$37.7K Hold
16,750
– – 0.02% 157
2025
Q1 		$35.8K Hold
16,750
– – 0.02% 151
2024
Q4 		$40.5K Hold
16,750
– – 0.02% 154
2024
Q3 		$40.9K Hold
16,750
– – 0.02% 159
2024
Q2 		$43K Hold
16,750
– – 0.02% 152
2024
Q1 		$48.9K Buy
+16,750
New +$46.8K 0.03% 149

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sage Capital Management's ORMP Position: Q2 2026 in Review

Sage Capital Management held its Oramed Pharmaceuticals (ORMP) position steady in Q2 2026 at 17,977 shares worth $86.5K. The position accounts for 0.03% of the portfolio, ranked #162.

Sage Capital Management first reported a position in ORMP in Q1 2024 and has held it in 10 quarters since. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Sage Capital Management held 17,977 shares of Oramed Pharmaceuticals worth $86.5K as of Q2 2026.
  • Sage Capital Management left its Oramed Pharmaceuticals share count unchanged in Q2 2026.
  • Oramed Pharmaceuticals made up 0.03% of Sage Capital Management's portfolio in Q2 2026, its #162 holding.
  • Sage Capital Management first reported a position in Oramed Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Sage Capital Management's 13F filing for Q2 2026, filed 20 Jul 2026.